Fireinthehole...you can't say that on this board. the gerontologists are liable to publically shame you.
Candidly if INCY currently derives $17bil market cap from jakafi with indications for MF, ET and recently granted PV and the rest of their pipeline is under trial development, conservatively GERN could easily take $12Bil worth of market cap from them. Not sure how this all breaks down wrt to the Janssen deal but it certainly indicates a very significant upside on approval for GERN's coffers.
Church of Gerontology, investing in real estate and showcasing the human need for inclusion whilst bankrupting it's members, sounds more like the Church of Scientology to me. Thumbs down if you agree.
get Chippy to trade in one of his porches for some GERN shares to show he has some real skin in the game and I wont vote my proxy.
....this was the critical point made, Jakafi will live or die by this trial as will IMET. The duel is scheduled for high noon some time in the near future, maybe, hopefully perhaps. (sound track for The Good Bad & Ugly playing in the background)
eieio go play your old McDonald farmer 8 track backwards. You may learn something.
Jocko your flooding the board with your multiple pumptard palace trolls. I'm not recommending to buy...I never do. As per all my board posts.
and GERNY is the laughing stock of the biotech sector. Had I not been a bag holder for 18 months I could have moved on to greener pastures.
Realistically the SP based on the frwd trial design by Janssen should put us back up to $5 range...failing that this stock has a broken wheel. You are overjoyed with a 7 cent rally Joko....now I find that's just pathetic. That or you're laughing to the bank with those 100,000 more shorts added after close. Tomorrow is options expiration. Will the $4.00 calls be taken out?
U liverstone, we are looking at comparative entry points for related stocks. You keep harping that INCY's drug is worthless yet their market cap is $17 billion and still GERN hasn't been able to get their's off the ground in over two years on this latest MF indication.(two years of reading conspiracy and excuses is wearing thin) Mayo and now Janssen had to do it for them. The J&J SP IS lower than INCY's but sure INCY's MC is dwarf by comparison. But why is GERN's SP & MC so low and so slow to yet recover? All the hype doesn't realistically add share holders confidence and neither does the hype attract new buyers. If anything people are distracted and turned off by all the mindless pumping.
with a shortened phase ll MF trial in the works and extensive safety trial data from other indications I suspect some special designation approval could very well be in the works. A possible buy out could probably come around the same time. Not sure what that would be but a far cry from the $263 PCYC went for.
INCY's failed drug has given them a market cap of $17bil and SP of $107, higher than that of J&J's SP of $101. GERN is exactly where er were 18 months ago in drug development just prior to the FDA hold.
you just have to know when to fold them. Their June studies if any good shouls bring the SP back up there. GERN on the other hand is still trading below $4 when with where it's at in the MF trial launch stage and Janssen partnership the SP should reflect levels prior to the hold and after the private placement in the high $4's and mid $5's last year in Jan.- Feb. + an additional partnership premium of a couple bucks. Until it gets back up to $6-$7 I figure it's all game playing.
Cottontail never mind keeping an eye, I've been sitting on this egg for over 18 months and all I have is a #$%$ to show for it.
after 500 patients in trials on IMET as Biopearl said starting with CLL, then Lung, then breast, then MM, then brain, then childhood tumors, then MF, MDS and so on the entire liver issue hold was a white elephant that delayed IMET for a full year. Why did it take the FDA so long to decide on investigating potential toxicity?
That lag time will be much condensed wrt IMET taking over an existing market share that's worth $17billion right now. I expect a buyout if things go well on these trials. Janssen won't let this one get away. But we're still months if not a year away. Speculation will help gain momentum as positive trial updates are announced (as per presentation yesterday). Investors will want to get on board early and with what IMET's already shown this will show some good upside shortly.